Kornimate/medical-research-clean huggingface dataset:
sheffield multiple rib fractures study:

Conditions: Rib Fractures

Summary: an observational study to derive clinically relevant and predictive rib fracture classification systems, based on retrospective and prospective cohorts, incorporating assessment of proms (patient reported outcome measures) and healthcare utilisation

the aim of this study is to derive radiology-based classifications of rib fractures and to test whether such classifications have a value in the prediction of clinical outcomes and patient reported outcome measures. the first aspect of work is to analyse existing radiology investigations (plain chest radiography (cxr) and derive classifications of rib fractures that, in the retrospective cohort of operated and non-operated cases, could have potential value in the guidance of management and prediction of clinical outcomes. the second aspect will be to evaluate the feasibility of collection of patient reported outcome measures in patients suffering multiple rib fractures, which will be used to assess the impact of the radiological classifications. the indications for surgery will remain according to current clinical practice and the management algorithms that have been developed previously in the department.

Eligibility criteria:
inclusion criteria: * multiple simple rib fractures * flail chest exclusion criteria: -

Keywords: multiple rib fractures, frail chest
anti-inflammatory effect of aerobic exercise in individual with increased cardiovascular risk

Conditions: Inflammation

Summary: aerobic physical activity attenuates systemic inflammatory activity in individuals with cardiovascular risk.

background: observational studies suggest that exercise has anti-inflammatory effect, however this idea has not been definitively confirmed by randomized clinical trials. objective: to test the hypothesis that aerobic exercise attenuates systemic inflammatory activity in individuals with cardiovascular risk. methods: randomized controlled trial, which included 68 sedentary individuals, with at least two risk factors for coronary heart disease or established cardiovascular disease. the volunteers were randomized to 3 months of supervised aerobic training or just advice when healthy lifestyles. c-reactive protein (crp) was measured by the method of high sensitivity before and after 3 months of intervention.

Eligibility criteria:
inclusion criteria: - individuals with are between 40 to 70 years, no regular exercise, and at least two risk factor for cardiovascular disease (diabetes, hypertension, dyslipidemia, smoking) or documented cardiovascular disease. exclusion criteria: - incapacity to exercise.

Keywords: exercise
spiral strapping for improving upper limb functions

Conditions: Stroke; Splints; Physical Disability

Summary: upper limb recovery after stroke is unacceptably poor with almost half of stroke survivors likely to regain some functional use. the rehabilitation process for upper extremity for individuals with stroke is of long duration and clinicians face the challenge of identifying a variety of assistive appliances that may be adapted and graded to facilitate this process. one of these appliances that is widely used in rehabilitation is splint and strapping. therefore, this study aims to investigate the effectiveness of this modality in rehabilitation of the upper limb in stroke survivors.

stroke often results in spasticity and associated motor impairments in the upper limb spasticity in the upper limb commonly interferes with its motor activities, and results in impairments in the upper limb muscles. persistent upper limb impairments can lead to limitations in activities of daily living, and quality of life. assistive devices to facilitate the use of the hemiplegic upper extremity are considered to be the most important modalities in improving the functions of the upper limb. the splint is one of the most assistive tools in the rehabilitation of such individuals. the supportive and corrective functions provided by upper limb and hand splints have been shown to inhibit spasticity and promote the capabilities of the upper limb in individuals with stroke this study aims to evaluate the effectiveness of spiral strapping on inhibition of spasticity and improving upper limb functions in individuals with chronic stroke.

Eligibility criteria:
inclusion criteria: the inclusion criteria were as follow: * participants were diagnosed as chronic stroke patients. * participants were selected to be in the spastic phase. * the degree of spasticity in the affected upper limbs, was ranged between grades (1, 1+\&2) according to modified ashworth scale. * participants were all between 50 and 60 years old, of both sexes. * participants were cognitively able to understand and follow instructions. * participants had the ability to extend their wrist joints at least 20° and ﬁngers 10° from full ﬂexion. this range allowed participants to engage easily in performing a designed functional program. exclusion criteria: the exclusion criteria were as follow: * participants who were with any orthopedic condition or fixed deformity that interfere with the upper limb functions. * participants who were with spasticity of more than score 2 according to the modified ashworth scale. * participants who had cognitive or perceptual problems. * participants with seizures, visual impairments, or auditory problems. * participants who had shoulder pain on a visual analogue scale of \> 6/10. * participants who had botulinum toxin in the upper extremity musculature six months before baseline assessment.

Keywords: stroke upper limb functions spiral strapping
safety and efficacy of alc in breast cancer in subjects with fatigue

Conditions: Breast Cancer

Summary: the objective of this study is to evaluate the efficacy and safety of alc in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy.

the objective of this study is to evaluate the efficacy and safety of alc in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy

Eligibility criteria:
inclusion criteria: * stage 0-iii breast cancer in which adjuvant radiation is indicated; * qualifying brief fatigue inventory (bfi) score 6. - exclusion criteria: * medication to treat or manage fatigue and pain * use of erythropoietin to control anemia * clinical evidence of hypothyroidism or hyperthyroidism

Keywords: breast cancer
smart study: a study of re-treatment with mabthera (rituximab) in patients with rheumatoid arthritis who have failed on anti-tnf alfa therapy

Conditions: Rheumatoid Arthritis

Summary: this study will compare the efficacy and safety of re-treatment with 2 doses of mabthera (rituximab) in patients with active rheumatoid arthritis (ra) who have previously experienced an inadequate response or intolerance to anti-tumor necrosis factor (anti-tnf) therapies etanercept, infliximab or adalimumab therapy. all patients will receive infusions of 1000 mg intravenous (iv) mabthera on days 1 and 15; at week 24 patients who have demonstrated a moderate or good response will be randomized to receive re-treatment with either 1 or 2 additional infusions of 1000 mg iv mabthera. the anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>18 years of age * ra for \>=6 months * receiving outpatient treatment * ongoing treatment with methotrexate for \>=3 months, stable for \>=1 month * inadequate response or intolerance to etanercept, infliximab or adalimumab exclusion criteria: * previous treatment with mabthera * concurrent treatment with any anti tnf-alfa therapy or biologic therapy * previous treatment with any investigational cell-depleting therapies
new double epigenetic regimen in the treatment of relapsed or refractory acute myeloid leukemia

Conditions: Acute Myeloid Leukemia; Refractory Acute Leukemia; Relapsed Adult AML

Summary: this study is to investigate the therapeutic efficacy and side effect of chidamide, azacitidine combined with priming hag regimen for relapsed or refractroy acute myeloid leukemia


Eligibility criteria:
inclusion criteria: * adults aged ≥ 18 and ≤ 70 years * patients diagnosed with aml according to 2016 who myeloid malignant disease diagnosis standard (non-apl) * patients with aml must meet one of the following criteria, a or b: a: refractory aml disease was defined as follows: (1) failure to attain cr following exposure to at least 2 courses of standard or intensive induction therapy; or (2) bone marrow leukemia cell decline index (bmcdi) \ 20% after 1 course of standard or intensive induction therapy. b: relapsed aml disease was defined as follows: (1) reappearance of leukemic blasts in the peripheral blood after cr; or (2) detection of ≥ 5% blasts in the bm not attributable to another cause (e.g., bm regeneration after consolidation therapy); or (3) extramedullary relapse. * ecog performance status score less than 3 * expected survival time ˃ 3 months * patients without serious heart, lung, liver, or kidney disease * ability to understand and voluntarily provide informed consent exclusion criteria: * patients who are allergic to the study drug or drugs with similar chemical structures * pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception * active infection * active bleeding * patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment * patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met * liver function abnormalities (total bilirubin \> 1.5 times the upper limit of the normal range, alt/ast \> 2.5 times the upper limit of the normal range or patients with liver involvement whose alt/ast \> 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine \> 1.5 times the upper limit of the normal value) * patients with a history of clinically significant qtc interval prolongation (male \> 450 ms; female \> 470 ms), ventricular heart tachycardia and atrial fibrillation, ii-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment * surgery on the main organs within the past six weeks * drug abuse or long-term alcohol abuse that would affect the evaluation results * patients who have received organ transplants (excepting bone marrow transplantation) * patients not suitable for the study according to the investigator's assessment

Keywords: chidamide azacitidine priming regimen
csdcs on functional mobility in parkinsons disease

Conditions: Parkinson Disease

Summary: parkinsons disease is a progressive neurological disorder marked by a decline in the efficacy of dopaminergic synapses in the nigrostriatal pathway, causing motor disturbances. resting tremor, bradykinesia, and muscle rigidity are the most prominent motor features. these factors result in gait impairments, including slowness and freezing. the primary treatment for the disease is medication. however, while medication does reduce motor symptoms, prolonged usage may lead to an increase of dyskinesias and a worsening of a patients clinical condition. thus, alternative therapies, such as cerebellospinal direct current stimulation (csdcs), have gained popularity. studies suggest that csdcs may be an effective approach to mitigate gait disorders in this patient population. kinesiotherapy is an established therapeutic method that has been demonstrated to promote functional mobility and improve gait. to date, the combination of kinesiotherapy and csdcs has not been tested, thus the purpose of this study is to evaluate the effectiveness of this combined therapy for enhancing functional mobility in parkinsons disease patients. the goal of this study is to assess the efficacy of blending csdcs and kinesiotherapy for improving patients functional mobility in parkinsons disease. two groups of volunteers will be assigned: i) actual csdcs + kinesiotherapy, and ii) sham csdcs + kinesiotherapy. the full procedure involves 10 therapy sessions conducted across two weeks.


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of pd provided by a neurologist * regular dopaminergic drug treatment (at least three months of use) * aged 40 years or over * staging i to iv on the modified hoehn and yahr scale exclusion criteria: * other neurological disorders, postural hypotension, vestibular, musculoskeletal or visual disorders that compromise performance in the proposed tests * other osteoarticular diseases in the lower limbs that interfere with performance and locomotion * a montreal cognitive assessment (moca) score of less than 21 points * have undergone previous surgery for pd

Keywords: gait training parkinson disease functional mobility csdcs
effects of late dinner against early dinner on weight loss healthy obese women

Conditions: Obesity; Overweight

Summary: the aim of the present study is to test whether late eating dinner could affect the amount of weight loss in healthy obese women in a weight-loss program.


Eligibility criteria:
inclusion criteria: * must have body mass index (bmi) between 27-35 kg/ m². * must be able to have moderate exercise. * must be interested to have weight loss. exclusion criteria: * participating in a research project involving weight loss or physical activity in the previous six months. * pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months. * taking medication that could affect metabolism or change body weight. * report heart problems, chest pain, and cancer within the last five years. * smoking * menopause * diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Keywords: weight loss dietary pattern late dinner early dinner
a study of lumigan® rc in the clinical setting

Conditions: Glaucoma, Primary Open Angle; Ocular Hypertension

Summary: this study will evaluate bimatoprost 0.01% (lumigan® rc) in patients with elevated intraocular pressure (iop) due to primary open angle glaucoma (poag) or ocular hypertension (oht) in a clinical setting.


Eligibility criteria:
inclusion criteria: * elevated iop due to either primary open-angle glaucoma or ocular hypertension * determined by the treating physician to require treatment with lumigan® rc exclusion criteria: * none
inhaled heparin for hospitalised covid-19 patients

Conditions: Covid19

Summary: this meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled trials and early phase studies. individual studies will be conducted in multiple countries, including australia, the uk, the usa, ireland, argentina, brazil and egypt. adult patients admitted to the hospital with confirmed sars-cov-2 infection, who do not require immediate mechanical ventilation, will be randomised to inhaled nebulised heparin or standard care for up to 21 days or until the patient has no respiratory symptoms. all studies will collect a minimum core dataset. the primary outcome for the meta-trial is the proportion of patients who receive invasive mechanical ventilation censored at day 28. individual studies may have specific outcome measures in addition to the core set.


Eligibility criteria:
inclusion criteria: * patients admitted to hospital with covid-19 * no immediate requirement for mechanical ventilation (points 3-5 on the who ordinal scale) * age equal to or greater than 18 * able to provide informed consent exclusion criteria: * pregnant women * known allergy to heparin * participant in another clinical trial that is not approved for joint enrollment. * aptt\> 120 seconds, not due to anticoagulant therapy. * platelet count \<20 x 109 per l * lung bleeding. * uncontrolled bleeding * advanced neurological impairment * advanced oncological disease
extension study to evaluate the long term safety and efficacy of denosumab in the treatment of osteoporosis

Conditions: Osteopenia; Osteoporosis

Summary: the primary objective was to describe the safety and tolerability of up to 10 years or 7 years denosumab administration as measured by adverse event monitoring, immunogenicity and safety laboratory parameters in participants who previously received denosumab or placebo, respectively.


Eligibility criteria:
postmenopausal women who have attended the 20030216 (nct00089791) study month 36 visit will be eligible to participate if they meet the inclusion and exclusion criteria given below. inclusion criteria * subjects must sign the informed consent before any study specific procedures are performed and agree to receive denosumab 60 mg subcutaneous injection every 6 months * subjects must not have discontinued investigational product during the 20030216 study and must have attended the 20030216 study month 36 visit * subjects must be re-consented prior to (or at) the 24 month visit for participation beyond month 24. exclusion criteria * permanently non-ambulatory subjects (use of an assistive device eg, cane, walker, etc. is permitted) * missed 2 or more investigational product doses during the 20030216 study * any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures * developed sensitivity to mammalian cell derived drug products during the 20030216 study * unable to tolerate calcium supplementation during the last 6 months of participation in the 20030216 study (between the month 30 and month 36 20030216 study visits) * currently receiving any investigational product other than denosumab or having received any investigational product during the 20030216 study * current use of the following osteoporosis agents: bisphosphonates, calcitonin, fluoride, parathyroid hormone, selective estrogen receptor modulators, systemic oral or transdermal estrogen (except vaginal preparations and estrogen creams which are acceptable), strontium, or tibolone * for bone biopsy sub-study subjects only: known or suspected sensitivity or contraindication to tetracycline derivatives

Keywords: postmenopausal osteoporosis low bone density fractures low bone mass
carbetocin versus misoprostol in cases with placenta previa after c.s.

Conditions: Postpartum Hemorrhage

Summary: we will compare efficacy and safety of carbetocin with misoprostol in prevention of postpartum hemorrhage in placenta previa women after c.s.

postpartum hemorrhage was traditionally defined as blood loss in excess of 500 ml from a vaginal delivery or 1000 ml at cesarean section. it can result from uterine atony, retained placental tissue including that from abnormal placentation, maternal genital tract trauma and coagulopathies. (almog et al, 2011) * uterotonic agents (e.g. ergometrine, misoprostol) should be easily accessible. many units of an oxytocin infusion and/or rectal misoprostol during and after cesarean deliveries used to reduce the incidence of atony. -misoprostol has been widely recommended for the prevention of post-partum hemorrhage when other methods are not available. the most common regimen reported for the treatment of post-partum hemorrhage is rectally. (oladapo et al., 2012) * misoprostol is a prostaglandin e1 analogue. it has been investigated in the prevention of postpartum hemorrhage, using either the oral or rectal route of administration. (hofmeyr et al, 2009) * carbetocin is a long-acting oxytocin studied by dansereau et al.; 1999.they found that the carbetocin group of patients had a decreased incidence of pph and of the need for therapeutic oxytocics. the recommended dose of carbetocin is 100 mg given either im or slowly (over 1 minute). * placenta previa, placenta accreta, and vasa previa are important causes of bleeding in the second half of pregnancy and in labor. risk factors for placenta previa include prior cesarean delivery, pregnancy termination, intrauterine surgery, smoking, multifetal gestation, increasing parity, and maternal age. thus, placenta previa is a risk factor for post partum hemorrhage.2006 apr;107(4):927-41. placenta previa, placenta accreta, and vasa previa. oyelese y1, smulian jc.obstet gynecol

Eligibility criteria:
inclusion criteria: * women with a singleton pregnancy undergoing cesarean section after 37 weeks of gestation. exclusion criteria: * • women undergoing caesarean section with general anesthesia will be excluded, because carbetocin is licensed for use with regional anaesthesia only. * women undergoing caesarean section at less than 37 weeks of gestation. * hypertension with pregnancy. * cardiac and coronary diseases with pregnancy

Keywords: pph
assessment of complications, quality of life and easiness of use of implantable central venous access ports

Conditions: Cancer

Summary: this is a prospective, descriptive and observational study of the anticancer center practice


Eligibility criteria:
inclusion criteria: * patient with any cancer, requiring a central venous catheter * no contraindication for any surgery with local or complete anaesthesia exclusion criteria: * previous xylocaine or lidocaine allergy * clinic superior vena cava syndrome

Keywords: implantable central venous access ports, cancer
resq132ex-nmibc: expanded access use of recombinant bacillus calmette-guérin in nonmuscle invasive bladder cancer

Conditions: NMIBC

Summary: this expanded access protocol is designed to provide recombinant mycobacterium bcg (rmbcg) to patients with non-muscle invasive bladder cancer (nmibc) who are eligible to receive tice® bcg, may benefit from its use, and who are ineligible to participate in a clinical trial using rmbcg, or for other reasons cannot participate (eg, geographically unable to access a study site).


Eligibility criteria:
inclusion criteria: participants must meet all of the following criteria for inclusion in the study: 1. age ≥18 years old. 2. histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype (mixed histology tumors allowed if transitional cell histology is predominant histology). 3. ineligible to participate in a clinical trial using rmbcg or geographically unable to access a rmbcg clinical trial site. 4. voluntary written informed consent and agreement to comply with all protocol specified procedures and follow-up evaluations. exclusion criteria: participants with any of the following criteria are excluded from participation in the study: 1. other illness or condition, including laboratory abnormalities, which in the opinion of the investigator would exclude the participant from participating in this study. this includes, but is not limited to, serious medical conditions or psychiatric illness likely to interfere with participation in the study. 2. women who are pregnant or nursing. female participants of childbearing potential must have a negative pregnancy test and must adhere to using a medically acceptable method of birth control prior to screening and agree to continue its use during the study and for 30 days after the last dose of study drug, or be surgically sterilized (eg, hysterectomy or tubal ligation). women of childbearing potential are defined as any female who has experienced menarche and who is not permanently sterile or postmenopausal. postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. males must agree to use barrier methods of birth control while on study and for 90 days post last dose of study drug.